![]() ![]() There are also reservations over whether Relovair can fill the gap.ĬEO Witty is diversifying the group to reduce reliance on “white pills in Western markets,” the part of the business most vulnerable to generic competition and price cuts imposed by cash-strapped governments. It is now over the worst of its patent losses, although uncertainty remains about when top-selling lung drug Advair will face generic competition. GSK - trading at a near 50 percent premium to Astra, based on expected 2012 earnings - is emerging from a revenue trough caused by patent expiries and a slump in sales of diabetes pill Avandia, which was linked to serious heart risks. ![]() GSK's improving R&D returns contrast with the story at smaller British rival AstraZeneca Plc AZN.L, whose management admitted last week its productivity was at the lower end of the industry average. It also has four ready to be submitted for regulatory approval in the coming months - lung drug Relovair, Promacta for hepatitis C, a MEK inhibitor for melanoma and a new flu vaccine. ![]() The company now expects up to 30 programs to move into late-stage clinical development over next three years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |